Publications by authors named "Giulia Sorgentoni"

Claim this Profile
M
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α).
Cristina Aguzzi, Simona De Summa, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Massimo Nabissi, Giulia Sorgentoni

Biochem Biophys Rep· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Giulia Sorgentoni

Cancer Immunol Immunother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, Marco Maruzzo, Roberto Iacovelli, Giulia Sorgentoni

Eur Urol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, Yohei Okada, Francesco Massari, Giulia Sorgentoni

Cancer Immunol Immunother· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations.
Camillo Porta, Aristotelis Bamias, Roubini Zakopoulou, Zin W Myint, Nicolò Cavasin, Giulia Sorgentoni

Minerva Urol Nephrol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Matteo Santoni, Francesco Massari, Zin W Myint, Roberto Iacovelli, Martin Pichler, Giulia Sorgentoni

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.
Alessandro Rizzo, Veronica Mollica, Sara Merler, Franco Morelli, Giulia Sorgentoni

Expert Opin Drug Metab Toxicol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.
Alessandro Rizzo, Marco Oderda, Veronica Mollica, Sara Merler, Franco Morelli, Giulia Sorgentoni

Anticancer Drugs· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis.
Alessandro Rizzo, Sara Merler, Giulia Sorgentoni, Marco Oderda, Veronica Mollica

Expert Opin Drug Metab Toxicol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Inflamma-miRs as Potential Biomarkers of Cognitive Impairment in Patients Affected by Alzheimer's Disease.
Angelica Giuliani, Simona Gaetani, Giulia Sorgentoni, Silvia Agarbati, Maristella Laggetta

Front Aging Neurosci· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Narrative review: predicting future molecular and clinical profiles of prostate cancer in the United States.
Matteo Santoni, Alessia Cimadamore, Francesco Massari, Giulia Sorgentoni, Liang Cheng

Transl Androl Urol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Matteo Santoni, Francesco Massari, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Giulia Sorgentoni

Diagnostics (Basel)· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications.
Giulia Occhipinti, Emanuela Romagnoli, Matteo Santoni, Alessia Cimadamore, Giulia Sorgentoni

Front Genet· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors.
Matteo Santoni, Daniel Y Heng, Sergio Bracarda, Giuseppe Procopio, Michele Milella, Giulia Sorgentoni

Cancers (Basel)· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications.
Gaetano Aurilio, Francesco Piva, Matteo Santoni, Alessia Cimadamore, Giulia Sorgentoni

Int J Mol Sci· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients?
Vincenzo Di Nunno, Veronica Mollica, Lidia Gatto, Matteo Santoni, Giulia Sorgentoni

Ann Transl Med· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathogenetic Characteristics of Mesenchymal Stem Cells in Hidradenitis Suppurativa.
Anna Campanati, Monia Orciani, Giulia Sorgentoni, Veronica Consales, Annamaria Offidani

JAMA Dermatol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives.
Anna Campanati, Veronica Consales, Monia Orciani, Katia Giuliodori, Giulia Ganzetti, Giulia Sorgentoni

Psoriasis (Auckl)· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammation by Breast Implants and Adenocarcinoma: Not Always a Bad Company.
Monia Orciani, Giulia Sorgentoni, Fabiola Olivieri, Monica Mattioli-Belmonte, Giovanni Di Benedetto

Clin Breast Cancer· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TNF-α inhibitors reduce the pathological Th -Th /Th imbalance in cutaneous mesenchymal stem cells of psoriasis patients.
Anna Campanati, Monia Orciani, Raffaella Lazzarini, Giulia Ganzetti, Veronica Consales, Giulia Sorgentoni

Exp Dermatol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of somatostatin and its analogues on progenitor mesenchymal cells isolated from human pituitary adenomas.
Monia Orciani, Miriam Caffarini, Giulia Sorgentoni, Riccardo Antonio Ricciuti, Giorgio Arnaldi

Pituitary· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis